A first wave of molecular glue and heterobifunctional degraders mostly focused on well-validated targets. A second surge is now pushing into more novel target space. “We're on the cusp of a ...

Two decades of continuous efforts to develop heterobifunctional degraders have brought targeted protein degradation to an exciting and promising era of next-generation medicines. TPD by PROteolysis ...

The histone acetyltransferase KAT2A, and its paralog KAT2B have been identified as key drivers of tumor cell plasticity in small-cell lung cancer (SCLC). Researchers from Auron Therapeutics Inc. aimed ...